Quarterly Result7 Nov 2025, 08:12 pm
Shree Ganesh Remedies Limited Reports Q2 & H1FY26 Results with Sequential Growth and Resilient Profitability
AI Summary
Shree Ganesh Remedies Limited, a fast-growing CMO & CDMO based in India for Pharmaceutical Intermediates & Fine Chemicals, announced its financial results for Q2 & H1FY26. The company delivered sequential growth in Q2FY26, driven by higher volumes and steady execution across key client projects. Despite muted realisations and the impact of higher depreciation and finance costs, profitability remained resilient. The company is confident of sustaining its EBITDA margins in the range of 24-26% over the long term. Operationally, the new pilot facility is nearing completion, and a new agrochemical project in Europe is set to begin by Q4FY27. The company is also evaluating new opportunities in European and Japanese markets.
Key Highlights
- Sequential growth in Q2FY26 driven by higher volumes and steady execution across key client projects.
- Resilient profitability despite muted realisations and the impact of higher depreciation and finance costs.
- Confidence in sustaining EBITDA margins in the range of 24-26% over the long term.
- Substantial progress on the new pilot facility with expected completion in Q3FY26 and operations in Q4FY26.
- Approval from a European client for a new agrochemical project with commercial orders scheduled to begin by Q4FY27.